Inhaled Technosphere Insulin in Children with Diabetes: The INHALE-1 Extension Study [0.03%]
新型胰岛素吸入剂治疗儿童糖尿病的疗效和安全性研究(INHALE-1)：延长试验阶段
Roy W Beck,Lauren Kanapka,Roshanak Monzavi et al.
Roy W Beck et al.
Background: On completion of the INHALE-1 randomized controlled trial (RCT), an extension phase was completed to provide longer term safety data on use of technosphere insulin (TI) in children with diabetes. ...
Continuous Ketone Monitoring Captures Overt Ketosis in Type 1 Diabetes Caused by Empagliflozin, Low-Carbohydrate Diet, and Exercise [0.03%]
持续监测酮体可捕捉到由恩格列净、低碳水饮食和运动引起的1型糖尿病患者的生酮状态
Elisabeth Lawton,Linden Perz,Melissa-Rosina Pasqua et al.
Elisabeth Lawton et al.
Euglycemic ketosis can occur in individuals with type 1 diabetes when multiple metabolic stressors converge; however, early recognition is challenging without dedicated ketone monitoring. We report a case of a 30-year-old woman with type 1 ...
Association of Time in Tight Range with Microvascular Complications in Japanese Patients with Type 2 Diabetes Mellitus: A Multicenter Cross-Sectional Study [0.03%]
血糖在目标范围内时间与2型糖尿病患者的微血管并发症的相关性——一项多中心横断面研究
Keiichi Torimoto,Yosuke Okada,Tomoya Mita et al.
Keiichi Torimoto et al.
Background: To determine the correlation between time in tight range (TITR; 70-140 mg/dL) and prevalence of microvascular complications in patients with type 2 diabetes mellitus (T2DM). ...
Jay S Skyler
Jay S Skyler
Since the discovery of insulin in 1921, we have seen a constant stream of innovative insulin formulations designed to more closely mimic physiological insulin secretion in people with type 1 diabetes and insulin-requiring type 2 diabetes. T...
Pulmonary Safety and Clinical Considerations for Inhaled Insulin: A Comprehensive Review [0.03%]
吸入性胰岛素的肺安全性和临床考量的全面综述
Janet B McGill,Oscar M Mayer
Janet B McGill
In January 2006, Exubera® (Pfizer, New York, NY) became the first inhaled insulin to be approved by the U.S. Food and Drug Administration (FDA). However, Exubera was withdrawn from the market in 2007 due to low sales. Ongoing innovation in...
Satish K Garg,Zehra Haider,Christopher G Parkin
Satish K Garg
Steve V Edelman,Thomas C Blevins,Christopher G Parkin et al.
Steve V Edelman et al.
Afrezza inhaled insulin offers a unique alternative to subcutaneous insulin delivery, providing a rapid onset to effectively manage postprandial glucose spikes with a short duration of action that minimizes delayed postprandial hypoglycemia...
Potential Role of Inhaled Insulin in the Management of Gestational Diabetes Mellitus and Pediatric Type 1 Diabetes [0.03%]
吸入性胰岛素在妊娠期糖尿病和儿童1型糖尿病管理中的潜在作用
Lori M Laffel,Amy M Valent
Lori M Laffel
The management of diabetes in women with gestational diabetes and in children and adolescents with type 1 diabetes presents challenges that require therapeutic options that address the unique needs of these patients. Technosphere® insulin ...
Irl B Hirsch,Christopher G Parkin
Irl B Hirsch
The increasing prevalence of diabetes presents a substantial challenge to the U.S. health care system. Despite advancements in insulin formulations designed to mimic physiological patterns and the development of diabetes technologies such a...
Potential Applications of Inhaled Insulin in Diabetic Ketoacidosis Prevention and During Exercise: Two Case Presentations [0.03%]
吸入性胰岛素在糖尿病酮症酸中毒预防及运动中的潜在应用——2例报道
Michael C Riddell,Christopher G Parkin,Lauren V Turner et al.
Michael C Riddell et al.
Reliance on endogenous insulin remains a significant challenge for individuals with type 1 diabetes (T1D). Although current rapid-acting insulin analogs (RAA) and ultra-rapid-acting insulin analogs (URAA) can provide effective postprandial ...